Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
3.455
-0.205 (-5.60%)
Mar 13, 2025, 11:26 AM EDT - Market open
Relay Therapeutics Employees
Relay Therapeutics had 261 employees as of December 31, 2024. The number of employees decreased by 62 or -19.20% compared to the previous year.
Employees
261
Change (1Y)
-62
Growth (1Y)
-19.20%
Revenue / Employee
$38,341
Profits / Employee
-$1,293,900
Market Cap
585.70M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 261 | -62 | -19.20% |
Dec 31, 2023 | 323 | -4 | -1.22% |
Dec 31, 2022 | 327 | 82 | 33.47% |
Dec 31, 2021 | 245 | 86 | 54.09% |
Dec 31, 2020 | 159 | - | - |
RLAY News
- 14 days ago - Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - GlobeNewsWire
- 16 days ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 21 days ago - Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025 - GlobeNewsWire
- 27 days ago - Relay Therapeutics: A Precision Oncology Play Worth The Risk - Seeking Alpha
- 2 months ago - Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival - GlobeNewsWire
- 3 months ago - Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 3 months ago - Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - GlobeNewsWire